This article is more than 5 years old. Information may no longer be current.

Santen initiates phase 2a study of DE-122 for wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Santen has initiated a phase 2a clinical study of the efficacy and safety of intravitreal injections of DE-122 for the treatment of wet age-related macular degeneration, according to a joint press release from Santen and Tracon Pharmaceuticals.

The randomized controlled trial will assess DE-122 in combination with Lucentis (ranibizumab, Genentech) compared with ranibizumab alone in patients with wet AMD. The initiation of the study will trigger a $7 million milestone payment from Santen to Tracon, the release said.

Santen licensed the global development rights for ophthalmic uses of DE-122 from Tracon in 2014. It then filed an FDA investigational new drug application for the drug in 2015.

“The initiation of the trial represents an important opportunity to expand the scope of our endoglin antibodies to areas of significant unmet medical need beyond oncology,” Charles Theuer, MD, PhD, president and CEO of Tracon, said in the release. “Data generated to date suggest the novel mechanism of action of DE-122 has the potential to combine effectively with approved VEGF inhibitors, the current standard of care, in patients with wet AMD.”